Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
Pinkus Tober‐Lau, Henning Gruell, Kanika Vanshylla, Willi M. Koch, David Hillus, Philipp Schommers, Isabelle Suárez, Norbert Suttorp, Leif Erik Sander, Florian Klein, Florian Kurth
Abstract
To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.
Topics & Concepts
VaccinationVirologyTiterSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibodyMedicineCoronavirus disease 2019 (COVID-19)CoronavirusImmunology2019-20 coronavirus outbreakVirusOutbreakDiseaseInternal medicineInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies